Search Results
You are looking at 1 - 1 of 1 items for
- Author: Thomas H Claus x
- Refine by access: All content x
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Thomas H Claus in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Clark Q Pan in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Joanne M Buxton in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Ling Yang in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Jennifer C Reynolds in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Nicole Barucci in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Michael Burns in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Astrid A Ortiz in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Steve Roczniak in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by James N Livingston in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by Kevin B Clairmont in
Google Scholar
PubMed
Bayer HealthCare, Biotechnology, 800 Dwight Way, Berkeley, California 94701, USA
Search for other papers by James P Whelan in
Google Scholar
PubMed
Type 2 diabetes is characterized by reduced insulin secretion from the pancreas and overproduction of glucose by the liver. Glucagon-like peptide-1 (GLP-1) promotes glucose-dependent insulin secretion from the pancreas, while glucagon promotes glucose output from the liver. Taking advantage of the homology between GLP-1 and glucagon, a GLP-1/glucagon hybrid peptide, dual-acting peptide for diabetes (DAPD), was identified with combined GLP-1 receptor agonist and glucagon receptor antagonist activity. To overcome its short plasma half-life DAPD was PEGylated, resulting in dramatically prolonged activity in vivo. PEGylated DAPD (PEG-DAPD) increases insulin and decreases glucose in a glucose tolerance test, evidence of GLP-1 receptor agonism. It also reduces blood glucose following a glucagon challenge and elevates fasting glucagon levels in mice, evidence of glucagon receptor antagonism. The PEG-DAPD effects on glucose tolerance are also observed in the presence of the GLP-1 antagonist peptide, exendin(9–39). An antidiabetic effect of PEG-DAPD is observed in db/db mice. Furthermore, PEGylation of DAPD eliminates the inhibition of gastrointestinal motility observed with GLP-1 and its analogues. Thus, PEG-DAPD has the potential to be developed as a novel dual-acting peptide to treat type 2 diabetes, with prolonged in vivo activity, and without the GI side-effects.
